Catalyst Pharmaceuticals Stock News

Here is how Aravive (ARAV) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.

The consensus price target hints at a 33.3% upside potential for Catalyst (CPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate

Catalyst Pharmaceuticals (CPRX) reports preliminary sales figures for the fourth quarter. The company also provides its revenue guidance for 2022.

Catalyst Pharmaceuticals Inc (NASDAQ: Full story available on Benzinga.com

Catalyst Pharmaceuticals (CPRX) reported preliminary Q4 revenue estimates and 2022 outlook.Q4 2021 total revenues expected to increase ~24% Y/Y to ~$38M. Consensus Revenue Estimate for…

Catalyst Pharmaceuticals Inc CPRX anticipates Q4 FY21 sales of approximately $38 million (consensus of $38.09 million), up roughly 24% Y/Y. Get the Inside Access Traders Are Using to Profit More an

Catalyst Pharmaceuticals <> said the District Court entered summary judgment in favor of the company in a lawsuit against the FDA.The District Court''s order implements the decision

Catalyst Pharmaceuticals (CPRX) announced that the U.S

As the market begins to shift from high-growth, tech-fueled start-ups, one good long-term growth option is quality pharmaceutical stocks. The post 7 of the Top-Rated Pharmaceutical Stocks for Q1 appea

These quiet biotechs are tightly focused and practically alone in their markets.

They've strongly outperformed the market in the past, and they could easily do it again.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)s stock price traded up 2.4% during mid-day trading on Friday . The company traded as high as $6.90 and last traded at $6.88. 2,192 shares were traded during mid-day trading, a decline of 100% from the average session volume of 1,217,669 shares. The stock had previously closed at $6.72. Separately, HC [] The post Catalyst Pharmaceuticals (NASDAQ:CPRX) Trading 2.4% Higher appeared first on ETF Daily News .

Fisher Asset Management LLC bought a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 201,801 shares of the biopharmaceutical companys stock, valued at approximately $1,070,000. Fisher Asset Management LLC owned 0.20% of []

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) insider Gary Ingenito sold 3,612 shares of the firms stock in a transaction on Tuesday, December 7th. The shares were sold at an average price of $6.99, for a total transaction of $25,247.88. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Shares []

CORAL GABLES, Fla., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today announced that its collaboration partner DyDo Pharma ("DyDo") has initiated a Phase 3 registrational study in Japan to evaluate the efficacy and safety of Catalyst''s FIRDAPSE ® (amifampridine) 10 mg tablets for the treatment of Lambert-Eaton myasthenic syndrome ("LEMS").